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~ Fat Infiltrates In Endomyocardlal Biopsies Lack 
Spealflclty for the Diagnosis of Right Ventrlcular 
Oysplasla 
A, Burke, E, Arbtmtlnl, B, dot Belle, P, Morblnl, G, Spocchtn, R, Virmanl, 
It~tltuto Anrffoml~l PatoIOglca, P~lvln, italy: And the Armed Forces Institute of 
Pathology, Wa,~hlogton, OC, USA 
Baokground; It h~s boon ~toted that fat Infiltration -,3,21% in ondomyoo~rdtnl 
biops o~ (EMB) i~ 91,5% spoctflo for the diagnosis of right ventfl¢ttlnr dy~ptn- 
~t~1 (Aogolinl ot at, tat, J CaM/el, tgg341', ~40, However, the fmquenw ~nd 
oRtot,~ { fR! Infiltrates in normal prttionl~ nnd pt~tlonts with dll~ted o,rdiomy. 
op~tny (DCM) has not boon o~tonslvoly studied 
Mothoc/~; EMBs from 30g oonsoguflvo normal head donors (moan 1,4 :t 
0,6 biopsy fragments) oed 100 EMB~;! t"om p~tlont~ with idiopathto dilated 
o,~rdlomyopathy (moan ~,0 ~ f,1 fragment,) wore evaluated, The % f~t 
infiltration determined morphomotrte~lly, 
R¢~ulf~: FP.t wa~ present In 69/421~ biopBy tragmonl~ (16%) in p~tionfs 
wtlh DCM end 32/425 (B%) of donor biopsy fragments (p ~ 0,001, In biopsies 
with fat infiltration, the moan % fat infiltration was 2B ~ ~6% in patients with 
DCM and IB ~ t3% in danom (p ,~ 0,0P., Patlont~ with, 1 biopsy were mare 
IiWoIv to h~vo f~l thnn those with only f biopsy (~5% v¢~, 8%, p .  0,00f, 
Overall, the mann % f~f (nllltr~lion was 4,5% tn pntiont~ with DCM and 1 ,~,% 
in danom, bgt woo not normally dlstrlb~g~d, 
Cnncht~ion: Fat infiltrates are pro~ont in up to 25% el EMBs, may be ex. 
tenslva, nnd, when pm~ent, u~ually e~eood 5%, They am more common and 
e~en~lvo In DCM than normal controls, and am not indic~ttivo inthemselves 
el fight vonfrlcuh~r dy~pl,~t~, 
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8 • 1 •  Effects of Pentoxltyillne on Left Ventrlcular 
Performance In Patients With Idiopathic Dilated 
Csrdlomyopathy 
K, Sliwa, e, ~kudickv, G, Candy, T, Wisenbaugh, P, Sareli. Department of 
C~rdiotogy, Bnmgwanafh H~pih11. Univemity of the Wltwatemrand, 
Joh~lnnosbu~, South Air/ca 
Background: increased plasma levels of tumor necrosis tactor.~r (TNF-.) 
have been repealed in patients (pts) wltl~ heart failure. Pontoxttylhne, a xan- 
thine denved agent has boon sl~own to suppress or reduce the produetlon of 
TNF~, 
Mefhoc~; prospective, double blind, randomized, placebo controlled triel, 
~n which 28 pts with idiopathic dilated cardtomyopathy were randomized 
to pentox~lyllino 400 mg TDS or placebo. Clinical, echocardiographtc and 
radlonuclido evaluation wore pedorrned af baseline and after 6 months of 
treatment. 
Results: there was a significant improvement in tunetional capacity with 
pentoxilyllino (2.7 ~t 0.5 to 1.2 ~ 0,4, p < 0.00001 ), This was associated with 
a significant increment in election traction (22.3% to 38.7%, p = 0.00007) and 
prolongation o1 the E wave deceleration time (133 ,t 56 to 176 ~. 65 msec, p 
= 0.03). No significant changes wore observed in the placebo group TNF-. 
plasma levers significantly declined w~th pentoxifylline (6.5 ;~ 3 te 2.1 ~t~ 1 
pg/mt, p= 0.001). 
Conclusions: these results suggest that treatment with pentoxifylline is 
associated with a significant improvement ot symptoms and parameters of 
left ventricular systolic and diastolic performance in pts with idiopathic dilated 
cardiomyopathy. 
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~ Irbesartan Compared With Llslnoprll in Patient;  With 
Mild to Moderate Heart Failure 
N. Vilay, I.A. Alhaddad, D. Marly Denny, D. Ruff, M. Yasin, L. Yellen, 
S. Lwer, C. Bryson, C.-S. Lin, R.A. Wolf. Irbesartan Heart Failur~ Group: 
Wes,em Ca,diology Associates, Denver, CO, USA 
This pilot study compared the efficacy and safety of irbesadan (IRBE, 
BMS/Sanofi) with lisinopril (LIS). 134 patients (pts) with symptomatic heart 
failure (HF, NYHA Class II or III) and left ventricular ejection fraction (LVEF) 
~,10% were entered. Prior to entry, pts had received stable doses of diuretics 
(~4 d) and and angiotensin converting enzyme inhibitors (ACE-Is) (~_6 wks). 
Open-label ACE-I therapy was stopped when pts were randomized to IRBE 
37.5 mg QD (n = 66) or LIS 5 mg QD (n = 68), (tittered to 150 mg and 20 me, 
respectively), 12-week efficacy variables Included changes from baseline in 
Modified Naughton exorclso tolerance test (ETT), LVEF, and oardtofhoracie 
ratio (CTR), Baseline domogrephics wore comparable (moan age: 66 ym, 
LVEF: 27%, CTR: 0,54. and 73% and 2~.  of pta had NYHA Class II and III 
HF, mspoctlvoly), 
Err (aec) modinn chnng~ ~.VEF (onit~) moan change CTR (units) mean ch~t~ 
IRBE 7~,5; 7-t3~' 1 90 (015.3,64) --001 (-0,0~0,00) 
LI~ 65,0; 7-t24' 0~1 f 0 fi5-~,37) ~00t (- 003-~'~,01) 
RBth~75th quantlloB: vnf|m~ in 0 represent 95% confidence timit~ 
IRBE and LtS h~d Bimilar lotorBbility pmfile~, ilCtgding the inccdenco f 
worsening HF nnd seriooB adverse events. Both dntgs showed coreparab!e 
offi(~y end stmilar clinical outcomo~ tn pfs with mttd40.moderafo HF. 
Cpnct¢t,,,on: I~bostt~n was well tolerated when substituted for ACE-I in pts 
with chronic HF 
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~3- ]  Compelrlson of the Long-term Effecle of Can/ed!!o! 
and Amlodsmne On Le!t Ven~l¢mlar Function in 
Patients With Dilated (:a~!iomyopathy 
U,K, Mu0IIor, M. Wells, D Skudicky, P Sam!i. Elara~,(ar~lth Hose#el, 
Johannesburg, South Atnca 
In patients with severn heart faih!re the addition ot cawedd01 to diuretics, 
digoxin and ACE-inhibitor therapy has resulted in in a signilicant improve- 
ment ef left vontflcular function and a consequent rnductton in moctatity. 
Although t,als el amtodarono in patients with congeshve head failure have 
produced discordant results with regard to effects on survival, most stud- 
ies hav~ repo~nd a significant nse in left venmcufar ejection fraction during 
Iong-tem~ therapy. Tho present study was undertaken to directly compare the 
effect on left vontficutar function el the 2 dregs: 37 portents with ichopathic 
dilated cardiomyopathy (IDCMO) who remained in NYHA functional class It 
despite 6 months of treatment with diuretics, digoxtn and an ACE-inhibdo¢ 
(trandolaprit 4 mg daily or onalapnl t0 mg bd) were prospectively randem~d 
to receive either amiodarone 200 mg daily or canredtloi 25 mg bd in nddlren 
te their other medication. The ochocardiographtc left ventncular dimensions 
at end-diastole (EDD), end.systole (ESD), fractional shortening |FS), and 
radionuclido ejection fraction (EF) at randomization (O) and after 6 months 
of treatment are shown in the table. There were no significant differences m 
age or sex composition in the 2 groups and no death or hosptial admission 
occurred during the randomization prated. 
Cawechtot (n : 18) Amloda~one [n: 191 
O 6 month p e 6 month p 
Ago 51 7.* 97y 4B5,~ 11 ry 
EDD 66::;0.95crn 631086cm NS 63~085cm 62~:093crn NS 
ESD 57 ~ t.lcrn 52~ 11cm 0or 56~: tOcm 51111cm oat 
FS 13 1 ~ 52% 180 ~ 7 3% 0.03 13.2 ± 70% 173 ±: 7.8% 002 
EF 283 t 105% 348 t 14.5% 001 25.9 :t 10.7% 34.7 ." 139% OOt 
There were no significant differences between the two study groups at the 
time of randomisation or alter 6 months of treatment (both absolute values 
and percentage change). 
Conclusion: The addition of either carvedtlot or amiodarone to standard 
antifailure treatment in patients with IDCMO significantly improved left ven- 
tricular performance, but with neither agent proving superior. 
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[ '~  Early Weight Gain Intervention Requires Drugs Less 
to Decrease Heart Failure Re-admissions 
M. Bondmass, N. Bolger, G. Castro, B. Avitall. University of Illinois at 
Chicago. USA 
Background: Hypervolemia is a challenging clinical problem in the manage- 
ment of heart failure. The timing of interventions following weight gain may 
influence the type of therapy used and affect hospital readmission rates. 
Methods: Following a head failure admission, 64 patients (NYHA class 
Ill-IV, rn~ -,n age 61 .L 13, 67% female, 63% African American), used a home 
modem-type monitor for two months. Weight, heart rate, blood pressure, and 
oxygen saturation were transmitted aily. Patients were telemanaged utilizing 
treatment protocols consistent with current heart failure guidelines. Treatment 
protocols, for all variables, were equivalent with the exception of weight 
increase interventions. Pmtecol one (n = 34) dictated phone assessment, 
patient education, and/or diuretic changes at >__5 pound increases. Protocol 
two (n = 30) required phone assessment, patient education, and/or diuretic 
changes at increases of 2 to 4 pounds. All patients were instructed to weigh 
JACT: Fchnl:,.~ I~,~va ; t I~STRACI% ~ (~';d riga 
tlmmsolves daih/, UPon waking a1101 urination and bolero eating or drinkin 9 
Both groups wore frequently counseled on fluid and salt resfri~lons, wdh 
patmnt educason interventions inifiato(i before drug intervention~ 
Resu/ts: Data re1 both ptofOO01 groups demonstrate an 80% red~-'tion 
=n heart falture admiss=ons and hoa;lh care costs at three (p - 0001) an~ 
six month (p ~ 0,001) I~low up, Improvement in quality of life was also 
demonMmted (p ~ 0,00~), No sigefficanl diffemnc~ in any parameter were 
demonstrated betw~n greu~ e~c~ for the mrmber e! diure~ changes 
feq~n~ to p~'venl ex~¢at~on and ~k'~s~quent ho~al  r~ ao'nlisston, 
mqu~r~l ~fCan l ly  mum d~urelm changes ~m~red to the Z-4 pound 
Con,~s~On: Consi~enng the COst and s~de effects of diuretics we con- 
( ; l~  thai e~dy ~ mlenmnlwn for werghl gain tesu!fs in les~ (~vefa!! 
~ to ~ eza~efbatKm and hOS~t madrmss~,  We tunher 
conc I~ lha! Ihe ava=~f~/e l  o ~  da!a, v~.v ie  our mender, provrdes 
a raf1Onate for eady and safe teMmanagement interventions. 
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~ RNu~!i~n In ~r t  Fa!!um I[v~ts by Clinical 
Pha~Is t  !n~l ion :  Pharmacist In H~rt  Failure 
~ ~ t  Recommendation and Monit~ing 
(PHARM) Study 
WA. Gatlts~ V. HasseP~d, R L. Larsen. DJ  Whellan, CM O'Connor Duke 
thuvers~ty Medica~ Center, Dumam, Noah Carolina, USA 
Bac~'~: / :  The mult~d~scfpkna~y ~ tO managing heart tadure (HF) 
pa~ts  (ptS) has been shown to II1'tpl~DVe o~tcolnlleS. The role of a clinical 
pharmacist (CPh) m HF has not been evaluated. 
/ i , fe~:  181 pts evaluated m c*.,m~ with HF and left ventocufar dys- 
function (EF ~. 45) were ~ to interventto~ (IG) or control (CG) 
group. The IG received CPh rsed~abon evaluabon, Ihorapeu~c racommen- 
dabor~s to attending p~an,  and foX,w-up (FILl) te~emondonng. The CG 
moe~l  usual care. The primary endpomt was combined afl cause mortal~ 
and HF cfin~cal events (CE). A~ CE were adiud~cated by a blinded enc~oomt 
commdlee. 
Resume: Basehoa cha,-acteflst~cs were sm~ar except far slightly h~per 
age In IG. ~,~:~an FU was 5 months. Air cause mortality and HF events are 
shown m Table 1. CPh inten,=entlon reduced the combined endgomt of death 
and HF events. 
Tabk~ 1 IG In : 901 ~ In = 91 } P 
~.~'taf~/& HF Events 4 16 e 0G5 
AR Cab'SO I~tt~hl~, 3 S 047~ 
HF Events 1 tl 0 005 
Tectal Events 29 36 0 
8.t~.~an% TargetACEI 100150 100)  501125 100t - 00101 
Co~:/us~,n. The =mproved outcomes may be due to h~ghet ACEI dose 
ancVor closer FU. Outcomes in HF are improved w~th a CPh as a member of 
the multidisoplinary HF team 
3:15 
~ Susts ined in Vascular Endothe l ia l  Improvement  
Function After Short-term Dobutamine Infusion in 
Patients With Severe Chronic Congestive Heart 
Fai lure 
LV. Kaplon, R.N. Pami, M.B. Patel. D. Levy. J. A Strata, J. Shiranl. 
TH. LeJemtel, A~bert Einstein College of Medicine, Bronx. NY. USA 
The mechanisms responsible for sustained clinical benefits after a 72 hour 
infusion of dobutamine (D) are unclear. We hypothesize that by increasing 
peripheral blood flow for 72 hours D may exert a prolonged effect on vascular 
endothelial function. Accordingly, HR, brachial artery (BA) diameter (d) and 
velocity-time integral were measured by Doppler echocardiography in 13 
patrents w~th severe CHF (LVEF: 26 ± 2%) treated ~lh  D for 72 hours (mean 
dose: 3.75 .gJkg/min). Measurements were made at rest (R) and at peak 
reactive hyperemia (PRH), induced by 5 minutes of BA occhrsion. These 
data were recorded at baseline (BL), at 3 and 72 hours of D, and at 2 and 4 
weeks alter D infusion. BAd and total BA blood flow (BABF) at rest and PRH 
and the percent change in BAd (~BAd) induced by PRH were calculated. 
While resting BABF increased by 34 and 26 ml/min after 3 and 72 hours of 
D (p < 0.05 vs BL), PRH BABF and HR were unchanged. The effects of D 
infusion on BAd are shown in the table: 
ElL 3 hr 72 hr 2 wk 4 wk 
R BAd (mm) 4.41 4.51 4.33 4.39 4.40 
,~BAd (%) 9,1 9.7 15,5" 12.8" 9.5 
• p < 0.05 vs BL 
We conclude: A 72 hour mtu~on =~ ;,-~u~-~ .n ,mpreveme~t m vasC~..~ar 
endothelial funcf~on man~fost by o~BAd, whch cS ~u~amed for ~ weeks post 
mfusmn w~tho~ change in e~her resting or PRH BABF These ef~e¢ls o~ 
vascular endothelial function ~m slm~l~r tO that note~ after p,hys~Cai t!a~ntr~ 
=n ~evero chronic CHF 
Minimally Invnlvo Coronary 
RevlmculadzMion 
Monday, March 30, 1998, 2:00 p,m,-3:30 p.m, 
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incisions Ns ~ and AssoeiMed With !mpmve¢l 
Patient Setlsfe~km 
DH Adams, D Re, borough, GS Couper, LH  Calm. Bngt~.~m ,~;~ 
~ ~ H<~p,fa/. Bosfo,, MA, USA 
Background: Beginning in J~Jly t996, we performed mimmalty mvaswe vah~ 
surgery in t00 pal~eres (age range 30~4 years) mqumng aomc valve re- 
placement n : 47 (AVR) or mltral valve replacement n : t0 e~ repair n = 43 
(MVR) We have reviewed our in~al clinical results and surveyed patients 
after (hscharge to assess e ~  of this approach. 
Met,hods: Procedures were performed through a 6 cm nght parastemat 
mosmn wffh removal o~ the 2nd--3~ (AVR) or 3mt-4th (MVR) costal ca~- 
lages, or an upper pamal stemotomy (AVR) F ~  for the small ~ ,  
all other aspects of the procedures were ~entTcal to those pe,Aormed through 
a sfemotomy. 
Resume: There were 2 penoperatwe deaths in the AVR group (arrhylhmla 
on POD 4, hepatic tadure on POD t5) and no deaths in the MVR group. The 
only mtraoperatp,,e complK;ations encountered were a coronary sinus mlury 
(n = 1) and a local dtssactlon Of the ascending aorta at a vent site (n = t). 
The rned~an lenglh at stay (LOS) was 5 days in each group. Importantly, 
patwent satmfacllon was very high with these approaches because of t) 
boiler cosmattc re=-ults. 1) decreased inc~smnal pain. and 3) eaflmr func~onal 
recovery reflected =n a reduction rn the need for post-I'msp~al rehal~llta~on 
tacd~l~es. 
Conclusion; Our expenence demcnstTares mimmalty mvastve cardiac 
valve surgery is safe and associated w~th improved patient satisfaction and 
recovery. We believe these techniques are likely to be w~dely adopted 
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-~ Port  MIDCAB: Cl inical  and Access  Experience 
Ang iograph ic  Fo l low-up 
AC Galloway. G.H. R=bakove. RA. Espos[to. J.S Mdler, R.V. Anderson, 
F.G. Baumann. PM Buttenhem~, Wl. Ayata, E.A. Grosei, SB  Cohnn. New 
York Unn,.ers~ty MeScal Center. New York. IVY.. USA 
Background: This report was intended to revvew our clinK:al expenenco w=th 
both minimally mvaswe direct coronary artery bypass (MIDCAB) and Port- 
Access coronary artery bypass (PAl in an affempt to develop an apprppflata 
treatment algorithm. 
Methods: From 10/96 to 4,97, 18 pls underwent MIDCAB and 32 10is 
underwent PA. There were 39 men and 11 women (mean age 62 yrs, range 
34-82). All 18 MIDCAB pls had single vessel bypass (16 LIMA to LAD, 
2 RIMA to RCA). in the PA group 18 pts underwent single bypass, 9 pts 
had double bypass and 5 pts had tnple bypass (31 LIMA to LAD. 1 RIMA 
to RCA; 9 radml artery grafts. 5 saphenous veln grafts, 5 sequontinl grafts) 
Flee PA pts had concomitant valvular procedureS. Angiographic studies were 
performed pnor to discharge m 13 of 18 MIDCAB and 30 of 32 PA pts. 
Results: There were no myocardial infarohons, deaths or strokes in either 
group. With MIDCAB. 2 pts were converted to stemotomy, 1 pt was converted 
to PA due to a fragile LAD and 2 p'.s required angioplasty ( 1 for graft occlusion 
and I for a separate LAD lesion). With PA. 2 lots were converted to MIBCAB 
due to penpheral atherosclerosis. I pt had reoperotion for graft revision and 
pulmonary embotectorny and 1 pt requ|red angioglasty for graft occlusion. By 
angiography. LAD graft patenCy was 923% for MIOCAB and 100% for pp. 
The overall graft patef~cy was 97.9% for PA. 
Conclusions: We recommend selectwe, complementary use el MIDCAB 
and PA for single vessel LAD disease, based on clinical variables such as 
coronary f,rag~lity or peripheral vascular disease. With the PA technique LAD 
graft patency was 100%. and both multi*vessel mvasculanzation and con- 
comitent intracardiac valvular surgery was possible. These results demon- 
strate the expanding role of minimally invasive bypass surgery. 
;~ ~i~ ) 
